FDA Orders Foundayo Postmarketing Studies; Lilly Acquires CrossBridge Bio for Up to $300M
LLY sits 48% above its 52-week low of $623.78.
Summary
Eli Lilly announced the FDA has ordered postmarketing safety studies for its newly approved weight-loss drug, Foundayo, focusing on potential liver injury, cardiovascular events, gastric emptying, and lactation drug levels. Concurrently, Lilly will acquire CrossBridge Bio, a developer of dual-payload antibody-drug conjugates, in a deal valued at up to $300 million through upfront cash and milestone payments. This news follows the recent FDA approval and launch of Foundayo, a key growth driver for Lilly, and another significant acquisition earlier this month. While postmarketing studies are standard, the specific areas of concern for Foundayo introduce a degree of long-term risk and scrutiny for a critical product. The CrossBridge Bio acquisition, though a positive pipeline addition, is relatively small for Lilly and less impactful than the regulatory update on Foundayo.
At the time of this announcement, LLY was trading at $922.50 on NYSE in the Life Sciences sector, with a market capitalization of approximately $871.6B. The 52-week trading range was $623.78 to $1,133.95. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.